41552-82-3
Chemical Structure
N6-Cyclopentyladenosine
Synonym(s): CPA; UK-80882
- CAS No.: 41552-82-3
- Formula:C15H21N5O4
- Molecular Weight:335.36
IUPAC Name: (2R,3R,4S,5R)-2-(6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
InChIKey: SQMWSBKSHWARHU-SDBHATRESA-N
SMILES: OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3NC4CCCC4)O1)O)O
Biological Activity: N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N6-Cyclopentyladenosine | 99.95% | N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N6-Cyclopentyladenosine (Standard) | ≥98% | N6-Cyclopentyladenosine (Standard) is the analytical standard of N6-Cyclopentyladenosine (HY-103181). This product is intended for research and analytical applications. N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Klotz KN, et al. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91. [Content Brief]
- [2]. Soliño M, et al. Adenosine A1 receptor: A neuroprotective target in light induced retinal degeneration. PLoS One. 2018 Jun 18;13(6):e0198838. [Content Brief]
- [3]. Mlejnek P, et al. Apoptosis induced by N6-substituted derivatives of adenosine is related to intracellular accumulation of corresponding mononucleotides in HL-60 cells. Toxicol In Vitro. 2005 Oct;19(7):985-90. [Content Brief]
- [4]. Pospísil M, et al. N6-cyclopentyladenosine inhibits proliferation of murine haematopoietic progenitor cells in vivo. Eur J Pharmacol. 2005 Jan 10;507(1-3):1-6. [Content Brief]
- [5]. Schwierin B, et al. Effects of N6-cyclopentyladenosine and caffeine on sleep regulation in the rat. Eur J Pharmacol. 1996 Apr 11;300(3):163-71. [Content Brief]
- [6]. Normile HJ, et al. N6-cyclopentyladenosine impairs passive avoidance retention by selective action at A1 receptors. Brain Res Bull. 1991 Jul;27(1):101-4. [Content Brief]
- [7]. Mathôt RA, et al. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther. 1994 Feb;268(2):616-24. [Content Brief]
- [8]. Mathôt RA, et al. Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo. Br J Pharmacol. 1995 Oct;116(3):1957-64. [Content Brief]
- [9]. Jaishree J, et al. Individual and combined effects of N6-cyclopentyladenosine, flunarizine and diazepam on aminophylline-induced recurrent generalized seizures in mice. Pol J Pharmacol. 2003 Jul-Aug;55(4):559-64. [Content Brief]
